Seaport Therapeutics Reports Q2 2026 Financial Results

What Happened

• Seaport Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release dated August 3, 2026.
• The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8‑K filed August 3, 2026; the 8‑K states the furnished information is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Announcement date: August 3, 2026.
• Reporting period: quarter ended June 30, 2026 (Q2 2026).
• Press release provided as Exhibit 99.1 to the Form 8‑K (and an Inline XBRL cover page was included).
• Form 8‑K was signed by Lauren White, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), dated August 3, 2026.

Why It Matters

• The company has publicly released its quarterly earnings and other financial results; investors should review the Exhibit 99.1 press release for revenue, net income/loss, cash position, and any operational or pipeline updates that affect valuation.
• Because the release was furnished (not “filed”), it is disclosed for investor information but is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings.
• Retail investors should read the full press release and any related SEC filings to see the actual numbers and management commentary before making investment decisions.